引導式測驗 · 中等 等級
AI 在藥物發現中的目標識別測驗
測試的目標是假設與證據、證據類型、因果解釋、實驗驗證和生物學背景。
問題 1 的 8
What does a high target-disease score establish?
預覽每個問題8 問題
當您參加測驗時,就會出現答案和解釋。
- What does a high target-disease score establish?
- Proof that a drug will treat the disease safely
- A causal mechanism in every tissue
- A clinical benefit in patients
- A prioritized hypothesis supported by the platform’s included evidence
- Why inspect the evidence behind a target association?
- Evidence provenance is irrelevant after ranking
- Different data types answer different questions and may be indirect
- All evidence types establish the same causal effect
- The score replaces the source data
- What would strengthen a candidate-target hypothesis experimentally?
- Perturb the target in a relevant model and reproduce the effect with another method
- Increase the number of computational features only
- Use the same assay repeatedly without controls
- Advance directly to patient treatment
- Why might a genetically associated target still be a poor drug target?
- A target score measures drug delivery
- A disease association guarantees tractability
- It may be inaccessible to a drug or cause harmful effects in other tissues
- Genetic evidence always means the target is safe
- Which source evidence is most clearly indirect?
- A controlled target perturbation in disease-relevant cells
- A rescue experiment after perturbation
- An orthogonal biochemical assay
- A literature-mined association without experimental confirmation in the relevant tissue
- Why can correlated evidence sources overstate confidence?
- They prove the target is causal
- They improve clinical outcomes automatically
- They may reflect overlapping data rather than independent confirmation
- They necessarily contradict each other
- What context should be documented before target experiments?
- Tissue, disease stage, target isoform, and expected direction of effect
- Only the database color scheme
- The preferred lab meeting day
- A platform score without its sources
- Can AI prioritization demonstrate clinical benefit?
- Yes, if a cell experiment changes a marker
- No; clinical benefit requires later study of a therapy and its outcomes
- Yes, if the model has a high score
- Yes, if several databases agree